Exparel Approval History
FDA Approved: Yes (First approved October 28, 2011)
Brand name: Exparel
Generic name: bupivacaine liposome
Dosage form: Injectable Suspension
Company: Pacira Pharmaceuticals, Inc.
Treatment for: Pain
Exparel (bupivacaine liposome injectable suspension) is a long-acting non-opioid local analgesic for postsurgical local analgesia, and for use as a nerve block (interscalene brachial plexus block) to provide pain relief following shoulder surgeries.
Development History and FDA Approval Process for Exparel
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.